Summit Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Current Ratio Growth & History (SMMT)
Summit Therapeutics's current ratio was 9.87 for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.87 | −0.29 | −2.82% |
| 2024 | 2024-12-31 | 10.15 | 0.86 | +9.22% |
| 2023 | 2023-12-31 | 9.30 | −7.64 | −45.09% |
| 2022 | 2022-12-31 | 16.93 | 13.14 | +345.87% |
| 2021 | 2021-12-31 | 3.80 | −0.61 | −13.84% |
| 2020 | 2020-12-31 | 4.41 | −1.38 | −23.79% |
| 2019 | 2019-12-31 | 5.78 | — | — |
Summit Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 6.96 | 1.83 | +35.73% |
| Q1 2026 | 2026-03-31 | 7.41 | −3.23 | −30.34% |
| Q4 2025 | 2025-12-31 | 9.87 | −0.29 | −2.82% |
| Q3 2025 | 2025-09-30 | 3.80 | −4.51 | −54.31% |
| Q2 2025 | 2025-06-30 | 5.13 | 2.78 | +118.54% |
| Q1 2025 | 2025-03-31 | 10.63 | 3.66 | +52.61% |
| Q4 2024 | 2024-12-31 | 10.15 | 0.86 | +9.22% |
| Q3 2024 | 2024-09-30 | 8.31 | 6.51 | +361.11% |
| Q2 2024 | 2024-06-30 | 2.35 | −16.72 | −87.70% |
| Q1 2024 | 2024-03-31 | 6.97 | −7.25 | −51.01% |
| Q4 2023 | 2023-12-31 | 9.30 | −7.64 | −45.09% |
| Q3 2023 | 2023-09-30 | 1.80 | −6.42 | −78.08% |
| Q2 2023 | 2023-06-30 | 19.07 | 13.84 | +264.39% |
| Q1 2023 | 2023-03-31 | 14.22 | 9.84 | +224.96% |
| Q4 2022 | 2022-12-31 | 16.93 | 13.14 | +345.87% |
| Q3 2022 | 2022-09-30 | 8.22 | 3.73 | +83.27% |
| Q2 2022 | 2022-06-30 | 5.23 | −0.32 | −5.72% |
| Q1 2022 | 2022-03-31 | 4.38 | 2.66 | +155.28% |
| Q4 2021 | 2021-12-31 | 3.80 | −0.61 | −13.84% |
| Q3 2021 | 2021-09-30 | 4.49 | 1.63 | +57.14% |
| Q2 2021 | 2021-06-30 | 5.55 | — | — |
| Q1 2021 | 2021-03-31 | 1.71 | — | — |
| Q4 2020 | 2020-12-31 | 4.41 | −1.38 | −23.79% |
| Q3 2020 | 2020-09-30 | 2.85 | — | — |
| Q4 2019 | 2019-12-31 | 5.78 | — | — |
Summit Therapeutics current ratio trends
Over the last five fiscal years, Summit Therapeutics's current ratio increased from 4.41 to 9.87, a change of 5.46. The latest reported quarter, Q2 2026, shows 6.96.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗